COVID-19 Evidence Accelerator Will Analyze RWD On Remdesivir

By Beth Wang / August 17, 2020 at 2:34 PM
FDA is using real-world data to better understand and answer questions about potential COVID-19 therapies, and remdesivir is the next therapy in the spotlight. Through its real-world evidence public-private partnership, the COVID-19 Evidence Accelerator, the agency and its partners assessed hydroxychloroquine, and the partnership soon will apply a similar set of questions and analyses to remdesivir, which has become the standard of care for COVID-19. Remdesivir is currently available as a coronavirus therapy under an emergency use authorization from FDA...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.